MX362730B - Composición de ácidos grasos omega-3, zinc y hierro para el tratamiento del trastorno por déficit de atención e hiperactividad (tdah). - Google Patents
Composición de ácidos grasos omega-3, zinc y hierro para el tratamiento del trastorno por déficit de atención e hiperactividad (tdah).Info
- Publication number
- MX362730B MX362730B MX2013004549A MX2013004549A MX362730B MX 362730 B MX362730 B MX 362730B MX 2013004549 A MX2013004549 A MX 2013004549A MX 2013004549 A MX2013004549 A MX 2013004549A MX 362730 B MX362730 B MX 362730B
- Authority
- MX
- Mexico
- Prior art keywords
- omega
- zinc
- iron
- fatty acids
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2013004549A MX362730B (es) | 2013-04-23 | 2013-04-23 | Composición de ácidos grasos omega-3, zinc y hierro para el tratamiento del trastorno por déficit de atención e hiperactividad (tdah). |
| ARP140101549A AR095832A1 (es) | 2013-04-23 | 2014-04-09 | Composición farmacéutica oral útil para el trastorno del déficit de atención e hiperactividad, suplemento nutricional y alimento que la comprenden y proceso para preparar la composición |
| BR112015026764A BR112015026764A2 (pt) | 2013-04-23 | 2014-04-23 | composição de ácidos graxos ômega-3, zinco e ferro para o tratamento do transtorno por déficit de atenção e hiperatividade (tdah) |
| PCT/IB2014/060952 WO2014174468A2 (es) | 2013-04-23 | 2014-04-23 | Composición de ácidos grasos omega-3, zinc y hierro para el tratamiento del trastorno por déficit de atención e hiperactividad (tdah) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2013004549A MX362730B (es) | 2013-04-23 | 2013-04-23 | Composición de ácidos grasos omega-3, zinc y hierro para el tratamiento del trastorno por déficit de atención e hiperactividad (tdah). |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013004549A MX2013004549A (es) | 2014-10-23 |
| MX362730B true MX362730B (es) | 2019-02-05 |
Family
ID=51792461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013004549A MX362730B (es) | 2013-04-23 | 2013-04-23 | Composición de ácidos grasos omega-3, zinc y hierro para el tratamiento del trastorno por déficit de atención e hiperactividad (tdah). |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR095832A1 (pt) |
| BR (1) | BR112015026764A2 (pt) |
| MX (1) | MX362730B (pt) |
| WO (1) | WO2014174468A2 (pt) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7704542B2 (en) * | 2001-09-12 | 2010-04-27 | Xanodyne Pharmaceuticals, Inc. | Vitamin/mineral compositions with DHA |
| DE202007000949U1 (de) * | 2007-01-23 | 2007-04-12 | Vogel Lukas | Nahrungsergänzungsmittel, bilanzierte Diät oder Arzneimittel für besonders medizinische Zwecke |
-
2013
- 2013-04-23 MX MX2013004549A patent/MX362730B/es active IP Right Grant
-
2014
- 2014-04-09 AR ARP140101549A patent/AR095832A1/es not_active Application Discontinuation
- 2014-04-23 BR BR112015026764A patent/BR112015026764A2/pt not_active Application Discontinuation
- 2014-04-23 WO PCT/IB2014/060952 patent/WO2014174468A2/es active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013004549A (es) | 2014-10-23 |
| BR112015026764A2 (pt) | 2017-07-25 |
| AR095832A1 (es) | 2015-11-11 |
| WO2014174468A2 (es) | 2014-10-30 |
| WO2014174468A3 (es) | 2014-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY165048A (en) | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form | |
| TN2017000554A1 (en) | Novel combination for use in the treatment of cancer | |
| MX2016004487A (es) | Capsulas blandas de capa entérica que constan de ácidos grasos poli insaturados. | |
| GB2502032A (en) | Vitamin D composition | |
| BR112015031417A8 (pt) | forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem | |
| MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
| MX2016000294A (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
| EA201300175A1 (ru) | Таблетка с контролируемым трехфазным высвобождением, содержащая мелатонин, и способ ее изготовления | |
| NZ707636A (en) | Ingenol-derived compounds that can be used for treating cancer | |
| AR093252A1 (es) | Composicion farmaceutica oral utilizada como antiparasitaria y antidiarreica y procesos para prepararla | |
| MX355719B (es) | Composicion farmaceutica en forma de una suspension oral que comprende una fraccion flavonoica y goma de xantano. | |
| IN2013MU01111A (pt) | ||
| MX2015007945A (es) | Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas. | |
| MX2015010486A (es) | Composicion masticable para administracion oral y proceso para preparar la misma. | |
| MX2020006075A (es) | Composiciones farmaceuticas de bendamustina. | |
| MX2016011706A (es) | Formulaciones de progesterona. | |
| MX2016005645A (es) | Composicion farmaceutica topica de acitretina. | |
| MX2014005153A (es) | Proceso de obtencion y composicion farmaceutica de ketorolaco trometamina y clorhidrato de tramadol sublingual usado para el dolor. | |
| MX2015015681A (es) | Composicion farmaceutica que comprende fingolimod. | |
| MX362730B (es) | Composición de ácidos grasos omega-3, zinc y hierro para el tratamiento del trastorno por déficit de atención e hiperactividad (tdah). | |
| IN2013MU03428A (pt) | ||
| EA201591644A1 (ru) | Лекарственная форма, содержащая кризотиниб | |
| MX2015007749A (es) | Composicion farmaceutica de clorhidrato de amantadina-loratadina-p aracetamol para integrar una capsula, para el tratamiento de resfriados entre otras alopatias. | |
| UY35541A (es) | Composición de ácidos grasos omega-3, zinc y hierro para el tratamiento del trastorno por déficit de atención e hiperactividad (TDAH) | |
| UA74097U (ru) | Способ изготовления средства для лечения туберкулеза |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |